Research Article
Spore Powder of Ganoderma lucidum Improves Cancer-Related Fatigue in Breast Cancer Patients Undergoing Endocrine Therapy: A Pilot Clinical Trial
Table 1
Demographics of patients in each group.
| | Experimental group () | Control group () | -value |
| | (1) age (year) | | | | | mean (SD) | 51.3 (9.8) | 53.2 (8.7) | |
| | (2) Body mass index (kg/m2) | | | | | mean (SD) | 22.9 (3.8) | 23.2 (3.5) | |
| | (3) Menopausal status n (%) | | | | | Pre-menopause | 10 (40.0%) | 12 (52.1%) | | | Post-menopause | 15 (60.0%) | 11 (47.9%) | |
| | (4) Clinical stage (%) | | | | | Stage I | 8 (32.0%) | 7 (30.4%) | | | Stage II | 10 (40.0%) | 9 (39.2%) | | | Stage IIIA | 7 (28.0%) | 7 (30.4%) | |
| | (5) Treatment (%) | | | | | Surgery + endocrine therapy | 4 (16.0%) | 3 (13.1%) | | | Surgery + radiation + endocrine therapy | 4 (16.0%) | 4 (17.3%) | | | Surgery + chemotherapy + endocrine | | | | | Therapy | 11 (44.0%) | 10 (43.5%) | | | Surgery + chemotherapy + radiation + endocrine therapy | 6 (24.0%) | 6 (26.1%) | |
| | (6) Duration of endocrine therapy (%) | | | | | >6 Months to 3 years | 15 (60.0%) | 13 (56.5%) | | | >3 years to 5 years | 10 (40.0%) | 10 (43.5%) | |
| | (7) Physical Activity (%) | | | | | 2 (8.0%) | 1 (4.3%) | | | 7 (28.0%) | 10 (43.5%) | | | 12 (48.0%) | 9 (39.1%) | | | 4 (16.0%) | 3 (13.1%) | |
| | (8) Diet (%) | | | | | 0 | 3 (12.0%) | 2 (8.6%) | | | 1~2 | 7 (28.0%) | 6 (26.1%) | | | 3~4 | 8 (32.0%) | 9 (39. 2%) | | | 5 | 7 (28.0%) | 6 (26.1%) | |
|
|
